Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?
Otte
Andreas
A
Dierckx
Rudi A
RA
D000477:Alkylating Agents / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000517:prevention & control; D016393:Lymphoma, B-Cell / Q000737:chemistry; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000532:radiotherapy*; D009190:Myelodysplastic Syndromes / Q000517:prevention & control; D011379:Prognosis; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods; D012306:Risk; D013997:Time Factors; D015021:Yttrium Radioisotopes / Q000494:pharmacology
D000477:Alkylating Agents; D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan